AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
Log in

NASDAQ:NYMXNymox Pharmaceutical Stock Price, Forecast & News

$3.44
-0.02 (-0.58 %)
(As of 06/1/2020 12:15 PM ET)
Add
Compare
Today's Range
$3.42
Now: $3.44
$3.46
50-Day Range
$2.12
MA: $2.88
$3.45
52-Week Range
$1.32
Now: $3.44
$4.09
Volume765 shs
Average Volume127,469 shs
Market Capitalization$245.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Read More
Nymox Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$0.05 per share

Profitability

Net Income$-13,160,000.00
Net Margins-14,341.11%

Miscellaneous

EmployeesN/A
Market Cap$245.00 million
Next Earnings Date8/12/2020 (Estimated)
OptionableOptionable

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

How has Nymox Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NYMX shares have increased by 50.2% and is now trading at $3.44. View which stocks have been most impacted by Coronavirus.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Nymox Pharmaceutical.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) released its quarterly earnings data on Monday, March, 30th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The biopharmaceutical company earned $0.03 million during the quarter. Nymox Pharmaceutical had a negative net margin of 14,341.11% and a negative return on equity of 285.17%. View Nymox Pharmaceutical's earnings history.

Has Nymox Pharmaceutical been receiving favorable news coverage?

Headlines about NYMX stock have been trending somewhat positive this week, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nymox Pharmaceutical earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutNymox Pharmaceutical.

Are investors shorting Nymox Pharmaceutical?

Nymox Pharmaceutical saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,270,000 shares, an increase of 7.9% from the April 30th total of 3,030,000 shares. Based on an average daily trading volume, of 153,200 shares, the days-to-cover ratio is presently 21.3 days. Approximately 8.3% of the company's stock are sold short. View Nymox Pharmaceutical's Current Options Chain.

Who are some of Nymox Pharmaceutical's key competitors?

What other stocks do shareholders of Nymox Pharmaceutical own?

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 56)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55)

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (0.16%), Patriot Financial Group Insurance Agency LLC (0.10%), First Citizens Financial Corp (0.05%), Wedbush Securities Inc. (0.05%), Private Advisor Group LLC (0.04%) and Deutsche Bank AG (0.04%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View institutional ownership trends for Nymox Pharmaceutical.

Which major investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Nymox Pharmaceutical.

Which major investors are buying Nymox Pharmaceutical stock?

NYMX stock was bought by a variety of institutional investors in the last quarter, including First Citizens Financial Corp, Patriot Financial Group Insurance Agency LLC, Citigroup Inc., Jane Street Group LLC, WMS Partners LLC, Creative Planning, Deutsche Bank AG, and Paloma Partners Management Co. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson, and Randall J Lanham. View insider buying and selling activity for Nymox Pharmaceutical.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $3.44.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $245.00 million and generates $120,000.00 in revenue each year.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is www.nymox.com.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.